COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D01ZWC
|
|||
Drug Name |
RPH-104 + olokizumab
|
|||
Synonyms |
RPH-104 + CDP-6038
|
|||
Drug Type |
Combination drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2/3 | [1] | |
Therapeutic Class |
Antiviral Agents
|
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04380519) Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.